Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42


Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.

Timmers M, Roex G, Wang Y, Campillo-Davo D, Van Tendeloo VFI, Chu Y, Berneman ZN, Luo F, Van Acker HH, Anguille S.

Front Immunol. 2019 Jul 16;10:1613. doi: 10.3389/fimmu.2019.01613. eCollection 2019. Review.


CD56 Homodimerization and Participation in Anti-Tumor Immune Effector Cell Functioning: A Role for Interleukin-15.

Van Acker HH, Van Acker ZP, Versteven M, Ponsaerts P, Pende D, Berneman ZN, Anguille S, Van Tendeloo VF, Smits EL.

Cancers (Basel). 2019 Jul 22;11(7). pii: E1029. doi: 10.3390/cancers11071029.


Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia.

Van Acker HH, Versteven M, Lichtenegger FS, Roex G, Campillo-Davo D, Lion E, Subklewe M, Van Tendeloo VF, Berneman ZN, Anguille S.

J Clin Med. 2019 Apr 27;8(5). pii: E579. doi: 10.3390/jcm8050579. Review.


Host metabolites stimulate the bacterial proton motive force to enhance the activity of aminoglycoside antibiotics.

Crabbé A, Ostyn L, Staelens S, Rigauts C, Risseeuw M, Dhaenens M, Daled S, Van Acker H, Deforce D, Van Calenbergh S, Coenye T.

PLoS Pathog. 2019 Apr 29;15(4):e1007697. doi: 10.1371/journal.ppat.1007697. eCollection 2019 Apr.


Various Evolutionary Trajectories Lead to Loss of the Tobramycin-Potentiating Activity of the Quorum-Sensing Inhibitor Baicalin Hydrate in Burkholderia cenocepacia Biofilms.

Sass A, Slachmuylders L, Van Acker H, Vandenbussche I, Ostyn L, Bové M, Crabbé A, Chiarelli LR, Buroni S, Van Nieuwerburgh F, Abatih E, Coenye T.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02092-18. doi: 10.1128/AAC.02092-18. Print 2019 Apr.


Laser-induced vapour nanobubbles improve drug diffusion and efficiency in bacterial biofilms.

Teirlinck E, Xiong R, Brans T, Forier K, Fraire J, Van Acker H, Matthijs N, De Rycke R, De Smedt SC, Coenye T, Braeckmans K.

Nat Commun. 2018 Oct 30;9(1):4518. doi: 10.1038/s41467-018-06884-w.


BDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target?

van Ee TJ, Van Acker HH, van Oorschot TG, Van Tendeloo VF, Smits EL, Bakdash G, Schreibelt G, de Vries IJM.

Vaccines (Basel). 2018 Sep 19;6(3). pii: E65. doi: 10.3390/vaccines6030065. Review.


Coumarin Reduces Virulence and Biofilm Formation in Pseudomonas aeruginosa by Affecting Quorum Sensing, Type III Secretion and C-di-GMP Levels.

Zhang Y, Sass A, Van Acker H, Wille J, Verhasselt B, Van Nieuwerburgh F, Kaever V, Crabbé A, Coenye T.

Front Microbiol. 2018 Aug 21;9:1952. doi: 10.3389/fmicb.2018.01952. eCollection 2018.


The role of the common gamma-chain family cytokines in γδ T cell-based anti-cancer immunotherapy.

Van Acker HH, Campillo-Davo D, Roex G, Versteven M, Smits EL, Van Tendeloo VF.

Cytokine Growth Factor Rev. 2018 Jun;41:54-64. doi: 10.1016/j.cytogfr.2018.05.002. Epub 2018 May 16. Review.


Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion.

Van Acker HH, Anguille S, De Reu H, Berneman ZN, Smits EL, Van Tendeloo VF.

Front Immunol. 2018 Apr 10;9:658. doi: 10.3389/fimmu.2018.00658. eCollection 2018.


Targeting the Nonmevalonate Pathway in Burkholderia cenocepacia Increases Susceptibility to Certain β-Lactam Antibiotics.

Sass A, Everaert A, Van Acker H, Van den Driessche F, Coenye T.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02607-17. doi: 10.1128/AAC.02607-17. Print 2018 May.


Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation.

Capsomidis A, Benthall G, Van Acker HH, Fisher J, Kramer AM, Abeln Z, Majani Y, Gileadi T, Wallace R, Gustafsson K, Flutter B, Anderson J.

Mol Ther. 2018 Feb 7;26(2):354-365. doi: 10.1016/j.ymthe.2017.12.001. Epub 2017 Dec 8.


Elucidation of the mechanism behind the potentiating activity of baicalin against Burkholderia cenocepacia biofilms.

Slachmuylders L, Van Acker H, Brackman G, Sass A, Van Nieuwerburgh F, Coenye T.

PLoS One. 2018 Jan 2;13(1):e0190533. doi: 10.1371/journal.pone.0190533. eCollection 2018.


CD56 in the Immune System: More Than a Marker for Cytotoxicity?

Van Acker HH, Capsomidis A, Smits EL, Van Tendeloo VF.

Front Immunol. 2017 Jul 24;8:892. doi: 10.3389/fimmu.2017.00892. eCollection 2017. Review.


Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells.

Van Acker HH, Beretta O, Anguille S, De Caluwé L, Papagna A, Van den Bergh JM, Willemen Y, Goossens H, Berneman ZN, Van Tendeloo VF, Smits EL, Foti M, Lion E.

Oncotarget. 2017 Feb 21;8(8):13652-13665. doi: 10.18632/oncotarget.14622.


The Role of Reactive Oxygen Species in Antibiotic-Mediated Killing of Bacteria.

Van Acker H, Coenye T.

Trends Microbiol. 2017 Jun;25(6):456-466. doi: 10.1016/j.tim.2016.12.008. Epub 2017 Jan 12. Review.


Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity.

van Beek JJ, Gorris MA, Sköld AE, Hatipoglu I, Van Acker HH, Smits EL, de Vries IJ, Bakdash G.

Oncoimmunology. 2016 Sep 2;5(10):e1227902. eCollection 2016.


Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells.

Van Acker HH, Anguille S, Willemen Y, Van den Bergh JM, Berneman ZN, Lion E, Smits EL, Van Tendeloo VF.

J Hematol Oncol. 2016 Sep 29;9(1):101.


The Role of Reactive Oxygen Species in Antibiotic-Induced Cell Death in Burkholderia cepacia Complex Bacteria.

Van Acker H, Gielis J, Acke M, Cools F, Cos P, Coenye T.

PLoS One. 2016 Jul 20;11(7):e0159837. doi: 10.1371/journal.pone.0159837. eCollection 2016.


The Role of Efflux and Physiological Adaptation in Biofilm Tolerance and Resistance.

Van Acker H, Coenye T.

J Biol Chem. 2016 Jun 10;291(24):12565-72. doi: 10.1074/jbc.R115.707257. Epub 2016 Apr 21. Review.


Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.

Van den Bergh J, Willemen Y, Lion E, Van Acker H, De Reu H, Anguille S, Goossens H, Berneman Z, Van Tendeloo V, Smits E.

Oncotarget. 2015 Dec 29;6(42):44123-33. doi: 10.18632/oncotarget.6536.


Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials.

Van Acker HH, Anguille S, Willemen Y, Smits EL, Van Tendeloo VF.

Pharmacol Ther. 2016 Feb;158:24-40. doi: 10.1016/j.pharmthera.2015.11.008. Epub 2015 Nov 23. Review.


Managing risk of hepatitis B after sharps injuries.

De Schryver AA, Van Hooste W, Van Acker H, Claessens B, Haenen R, Van Crombrugge K, Godderis L.

BMJ. 2015 Oct 21;351:h5568. doi: 10.1136/bmj.h5568. No abstract available.


A Microplate-Based System as In Vitro Model of Biofilm Growth and Quantification.

Vandecandelaere I, Van Acker H, Coenye T.

Methods Mol Biol. 2016;1333:53-66. doi: 10.1007/978-1-4939-2854-5_5.


Genome-wide transcription start site profiling in biofilm-grown Burkholderia cenocepacia J2315.

Sass AM, Van Acker H, Förstner KU, Van Nieuwerburgh F, Deforce D, Vogel J, Coenye T.

BMC Genomics. 2015 Oct 13;16:775. doi: 10.1186/s12864-015-1993-3.


Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy.

Van Acker HH, Anguille S, Van Tendeloo VF, Lion E.

Oncoimmunology. 2015 Apr 1;4(8):e1021538. eCollection 2015 Aug. Review.


Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy.

Anguille S, Smits EL, Bryant C, Van Acker HH, Goossens H, Lion E, Fromm PD, Hart DN, Van Tendeloo VF, Berneman ZN.

Pharmacol Rev. 2015 Oct;67(4):731-53. doi: 10.1124/pr.114.009456. Review.



Lu P, Van Acker H, Waer P.

JBR-BTR. 2015 Jan-Feb;98(1):48-9.


Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner.

Anguille S, Van Acker HH, Van den Bergh J, Willemen Y, Goossens H, Van Tendeloo VF, Smits EL, Berneman ZN, Lion E.

PLoS One. 2015 May 7;10(5):e0123340. doi: 10.1371/journal.pone.0123340. eCollection 2015.


Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions.

Willemen Y, Van den Bergh JM, Lion E, Anguille S, Roelandts VA, Van Acker HH, Heynderickx SD, Stein BM, Peeters M, Figdor CG, Van Tendeloo VF, de Vries IJ, Adema GJ, Berneman ZN, Smits EL.

Cancer Immunol Immunother. 2015 Jul;64(7):831-42. doi: 10.1007/s00262-015-1688-2. Epub 2015 Apr 12.


Differential roles of RND efflux pumps in antimicrobial drug resistance of sessile and planktonic Burkholderia cenocepacia cells.

Buroni S, Matthijs N, Spadaro F, Van Acker H, Scoffone VC, Pasca MR, Riccardi G, Coenye T.

Antimicrob Agents Chemother. 2014 Dec;58(12):7424-9. doi: 10.1128/AAC.03800-14. Epub 2014 Sep 29.


The BCESM genomic region contains a regulator involved in quorum sensing and persistence in Burkholderia cenocepacia J2315.

Van Acker H, De Canck E, Van Nieuwerburgh F, Sass A, Deforce D, Nelis HJ, Coenye T.

Future Microbiol. 2014;9(7):845-60. doi: 10.2217/fmb.14.54.


Involvement of toxin-antitoxin modules in Burkholderia cenocepacia biofilm persistence.

Van Acker H, Sass A, Dhondt I, Nelis HJ, Coenye T.

Pathog Dis. 2014 Aug;71(3):326-35. doi: 10.1111/2049-632X.12177. Epub 2014 Apr 28.


Molecular mechanisms of antimicrobial tolerance and resistance in bacterial and fungal biofilms.

Van Acker H, Van Dijck P, Coenye T.

Trends Microbiol. 2014 Jun;22(6):326-33. doi: 10.1016/j.tim.2014.02.001. Epub 2014 Mar 2. Review.


Activity of disinfectants against multispecies biofilms formed by Staphylococcus aureus, Candida albicans and Pseudomonas aeruginosa.

Kart D, Tavernier S, Van Acker H, Nelis HJ, Coenye T.

Biofouling. 2014;30(3):377-83. doi: 10.1080/08927014.2013.878333. Epub 2014 Feb 28.


Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy.

Anguille S, Lion E, Van den Bergh J, Van Acker HH, Willemen Y, Smits EL, Van Tendeloo VF, Berneman ZN.

Hum Vaccin Immunother. 2013 Sep;9(9):1956-61. doi: 10.4161/hv.25373. Epub 2013 Jun 18. Review.


Biofilm-grown Burkholderia cepacia complex cells survive antibiotic treatment by avoiding production of reactive oxygen species.

Van Acker H, Sass A, Bazzini S, De Roy K, Udine C, Messiaen T, Riccardi G, Boon N, Nelis HJ, Mahenthiralingam E, Coenye T.

PLoS One. 2013;8(3):e58943. doi: 10.1371/journal.pone.0058943. Epub 2013 Mar 13.


Phenotypic and genotypic characterisation of Burkholderia cenocepacia J2315 mutants affected in homoserine lactone and diffusible signal factor-based quorum sensing systems suggests interplay between both types of systems.

Udine C, Brackman G, Bazzini S, Buroni S, Van Acker H, Pasca MR, Riccardi G, Coenye T.

PLoS One. 2013;8(1):e55112. doi: 10.1371/journal.pone.0055112. Epub 2013 Jan 28.


Molecular mechanisms of chlorhexidine tolerance in Burkholderia cenocepacia biofilms.

Coenye T, Van Acker H, Peeters E, Sass A, Buroni S, Riccardi G, Mahenthiralingam E.

Antimicrob Agents Chemother. 2011 May;55(5):1912-9. doi: 10.1128/AAC.01571-10. Epub 2011 Feb 28.


In vitro activity of temocillin against planktonic and sessile Burkholderia cepacia complex bacteria.

Van Acker H, Van Snick E, Nelis HJ, Coenye T.

J Cyst Fibros. 2010 Dec;9(6):450-4. doi: 10.1016/j.jcf.2010.08.015. Epub 2010 Sep 20.


Dilated cardiomyopathy caused by a novel TNNT2 mutation-added value of genetic testing in the correct identification of affected subjects.

Van Acker H, De Sutter J, Vandekerckhove K, de Ravel TJ, Verhaaren H, De Backer J.

Int J Cardiol. 2010 Oct 8;144(2):307-9. doi: 10.1016/j.ijcard.2009.03.003. Epub 2009 Mar 26.


Influence of GABA on the spectral and spatial coding of goldfish retinal ganglion cells.

Schellart NA, van Acker HF, Spekreijse H.

Neurosci Lett. 1984 Jul 13;48(1):31-6.


Supplemental Content

Loading ...
Support Center